We have previously created similar treatment for cancer based upon the NKG2D-ovarian cancer honing molecule [14, 15] or the Annexin A5 molecule [16, 17], which showed the potential clinical applications and the importance of using antigen-specific immunotherapy to reverse immune tolerance. The gene discussed is KLRK1; the disease is ovarian carcinoma.